vs
Side-by-side financial comparison of LESAKA TECHNOLOGIES INC (LSAK) and Vertex Pharmaceuticals (VRTX). Click either name above to swap in a different company.
LESAKA TECHNOLOGIES INC is the larger business by last-quarter revenue ($3.1B vs $3.0B, roughly 1.0× Vertex Pharmaceuticals). Vertex Pharmaceuticals runs the higher net margin — 34.5% vs 0.1%, a 34.4% gap on every dollar of revenue. On growth, LESAKA TECHNOLOGIES INC posted the faster year-over-year revenue change (16.0% vs 7.8%). Over the past eight quarters, LESAKA TECHNOLOGIES INC's revenue compounded faster (357.6% CAGR vs 6.3%).
Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
LSAK vs VRTX — Head-to-Head
Income Statement — Q4 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.1B | $3.0B |
| Net Profit | $3.6M | $1.0B |
| Gross Margin | — | 86.8% |
| Operating Margin | 1.2% | 38.1% |
| Net Margin | 0.1% | 34.5% |
| Revenue YoY | 16.0% | 7.8% |
| Net Profit YoY | — | 59.6% |
| EPS (diluted) | — | $4.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $3.1B | — | ||
| Q1 26 | — | $3.0B | ||
| Q4 25 | $178.7M | $3.2B | ||
| Q3 25 | $171.4M | $3.1B | ||
| Q2 25 | $168.5M | $3.0B | ||
| Q1 25 | $161.4M | $2.8B | ||
| Q4 24 | $176.2M | $2.9B | ||
| Q3 24 | $153.6M | $2.8B |
| Q2 26 | $3.6M | — | ||
| Q1 26 | — | $1.0B | ||
| Q4 25 | $3.6M | $1.2B | ||
| Q3 25 | $-4.3M | $1.1B | ||
| Q2 25 | $-28.4M | $1.0B | ||
| Q1 25 | $-22.1M | $646.3M | ||
| Q4 24 | $-32.5M | $913.0M | ||
| Q3 24 | $-4.5M | $1.0B |
| Q2 26 | — | — | ||
| Q1 26 | — | 86.8% | ||
| Q4 25 | 31.4% | 85.4% | ||
| Q3 25 | 30.9% | 86.5% | ||
| Q2 25 | 28.9% | 86.3% | ||
| Q1 25 | 27.5% | 86.9% | ||
| Q4 24 | 25.7% | 85.5% | ||
| Q3 24 | 22.6% | 85.8% |
| Q2 26 | 1.2% | — | ||
| Q1 26 | — | 38.1% | ||
| Q4 25 | 1.2% | 37.8% | ||
| Q3 25 | 0.2% | 38.6% | ||
| Q2 25 | -16.7% | 38.8% | ||
| Q1 25 | 0.4% | 22.7% | ||
| Q4 24 | 0.3% | 35.2% | ||
| Q3 24 | -0.0% | 40.3% |
| Q2 26 | 0.1% | — | ||
| Q1 26 | — | 34.5% | ||
| Q4 25 | 2.0% | 37.3% | ||
| Q3 25 | -2.5% | 35.2% | ||
| Q2 25 | -16.9% | 34.8% | ||
| Q1 25 | -13.7% | 23.3% | ||
| Q4 24 | -18.4% | 31.4% | ||
| Q3 24 | -3.0% | 37.7% |
| Q2 26 | — | — | ||
| Q1 26 | — | $4.02 | ||
| Q4 25 | $0.04 | $4.64 | ||
| Q3 25 | $-0.05 | $4.20 | ||
| Q2 25 | $-0.40 | $3.99 | ||
| Q1 25 | $-0.27 | $2.49 | ||
| Q4 24 | $-0.40 | $3.62 | ||
| Q3 24 | $-0.07 | $4.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.2B | — |
| Total DebtLower is stronger | $3.4B | — |
| Stockholders' EquityBook value | — | $19.4B |
| Total Assets | $11.7B | $26.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $1.2B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $69.5M | $6.6B | ||
| Q3 25 | $72.2M | $6.3B | ||
| Q2 25 | $76.5M | $6.4B | ||
| Q1 25 | $71.0M | $6.2B | ||
| Q4 24 | $60.6M | $6.1B | ||
| Q3 24 | $49.7M | $6.5B |
| Q2 26 | $3.4B | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $216.8M | — | ||
| Q3 25 | $208.1M | — | ||
| Q2 25 | $200.8M | — | ||
| Q1 25 | $194.7M | — | ||
| Q4 24 | $148.7M | — | ||
| Q3 24 | $148.5M | — |
| Q2 26 | — | — | ||
| Q1 26 | — | $19.4B | ||
| Q4 25 | $180.6M | $18.7B | ||
| Q3 25 | $170.4M | $17.3B | ||
| Q2 25 | $161.6M | $17.2B | ||
| Q1 25 | $185.2M | $16.5B | ||
| Q4 24 | $193.3M | $16.4B | ||
| Q3 24 | $184.2M | $15.6B |
| Q2 26 | $11.7B | — | ||
| Q1 26 | — | $26.5B | ||
| Q4 25 | $704.6M | $25.6B | ||
| Q3 25 | $652.9M | $24.9B | ||
| Q2 25 | $653.7M | $24.0B | ||
| Q1 25 | $649.2M | $22.9B | ||
| Q4 24 | $640.6M | $22.5B | ||
| Q3 24 | $551.9M | $22.2B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.20× | — | ||
| Q3 25 | 1.22× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.81× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSAK
Segment breakdown not available.
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
